Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; W. Geitzenauer; F. Prager; A. Rosin; G. Kornek; L. Vormittag; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5231.

ARVO Annual Meeting Abstract May 2005

Safety of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; C.A. Puliafito; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1378.

ARVO Annual Meeting Abstract May 2004

Optimized treatment parameters increase the selectivity of photodynamic therapy with Verteporfin

S.M. Michels; F. Hansmann; R. Michels; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3164.

ARVO Annual Meeting Abstract May 2003

Photodynamic Therapy Induces Expression of Vascular Endothelial Growth Factor (VEGF) and Pigment Epithelial Derived Factor (PEDF)

S.M. Michels; U. Schlötzer-Schrehard; G.O. Naumann; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2157.

Advertisement